Interference With the AMPKα/mTOR/NLRP3 Signaling and the IL-23/IL-17 Axis Effectively Protects Against the Dextran Sulfate Sodium Intoxication in Rats: A New Paradigm in Empagliflozin and Metformin Reprofiling for the Management of Ulcerative Colitis

Bibliographic Information
Authors: Youssef M.E.; Abd El-Fattah E.E.; Abdelhamid A.M.; Eissa H.; El-Ahwany E.; Amin N.A.; Hetta H.F.; Mahmoud M.H.; Batiha G.E.-S.; Gobba N.; Ahmed Gaafar A.G.; Saber S.
Journal: Frontiers in Pharmacology
Publisher: Frontiers Media S.A.
Publication Date: 16 August 2021
Volume / Issue: Volume 12
Article No.: 719984
ISSN: 16639812
DOI: 10.3389/fphar.2021.719984
Scopus: View on Scopus
Document Type: Article
Access: All Open Access; Gold Open Access; Green Open Access
Authors and Affiliations
Youssef M.E., Department of Pharmacology, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa, Egypt; Abd El-Fattah E.E., Department of Biochemistry, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa, Egypt; Abdelhamid A.M., Department of Pharmacology, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa, Egypt; Eissa H., Department of Clinical Pharmacology, Faculty of Medicine, Mansoura University, Mansoura, Egypt; El-Ahwany E., Department of Immunology, Theodor Bilharz Research Institute, Giza, Egypt; Amin N.A., Department of Hematology, Theodor Bilharz Research Institute, Giza, Egypt; Hetta H.F., Department of Medical Microbiology and Immunology, Faculty of Medicine, Assiut University, Assiut, Egypt, Department of Internal Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH, United States; Mahmoud M.H., Department of Biochemistry, College of Science, King Saud University, Riyadh, Saudi Arabia; Batiha G.E.-S., Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour, Egypt; Gobba N., Department of Pharmacology and Toxicology, College of Pharmacy, Misr University for Science and Technology, 6th of October City, Egypt; Ahmed Gaafar A.G., Department of Pharmacology and Toxicology, Faculty of Pharmacy, Port-Said University, Port-Said, Egypt; Saber S., Department of Pharmacology, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa, Egypt
Abstract
Empagliflozin and metformin are widely used for the treatment of type 2 diabetes. These drugs showed marked anti-inflammatory effects in different animal models via enhancing AMPK activity. Yet, the protective anti-inflammatory effects of their combination against ulcerative colitis have not been previously investigated. The current study aimed to explore the potential of empagliflozin/metformin combination to mitigate the DSS-induced rat colitis model. The modulating effects of empagliflozin and metformin on the AMPK/mTOR/NLRP3 axis and T cell polarization were delineated. In this study, distal colons were examined for macroscopic and microscopic pathological alterations. ELISA, qRT-PCR, and immunohistochemistry techniques were applied to detect proteins and cytokines involved in AMPK/mTOR/NLRP3 axis and T Cell polarization. Oral administration of empagliflozin (10 mg/kg/day) and metformin (200 mg/kg/day) combination alleviated colitis as revealed by the reduced disease activity index, macroscopic damage index, colon weight/length ratio, and histopathologic scoring values. Interestingly, empagliflozin/metformin combination significantly enhanced AMPK phosphorylation and depressed mTOR and NLRP3 expression leading to a subsequent reduction in caspase-1 cleavage and inhibition of several inflammatory cytokines, including IL-1β, and IL-18. Reduced mTOR expression and reduced IL-6 levels led to a reduction in Th17 cell polarization and maintenance. Together, the current study reveals that the protective effects of empagliflozin and metformin against DSS-induced colitis are fundamentally mediated via enhancing AMPK phosphorylation. Since adult humans with diabetes mellitus are at greater risk for developing inflammatory bowel diseases, clinical application of empagliflozin/metformin combination represents a novel therapeutic approach for treating diabetic patients with ulcerative colitis. © Copyright © 2021 Youssef, Abd El-Fattah, Abdelhamid, Eissa, El-Ahwany, Amin, Hetta, Mahmoud, Batiha, Gobba, Ahmed Gaafar and Saber.
Keywords
AMPK; dextran sulfate sodium; empagliflozin; IL-23/1L-17 axis 4; metformin; mTOR; NLRP3; ulcerative colitis; cryopyrin; dextran sulfate; hydroxymethylglutaryl coenzyme A reductase kinase; interleukin 17; interleukin 18; interleukin 1beta; interleukin 1beta converting enzyme; interleukin 23; interleukin 6; mammalian target of rapamycin; adult; animal experiment; animal model; animal tissue; antiinflammatory activity; Article; controlled study; descending colon; disease activity; drug repositioning; enzyme linked immunosorbent assay; enzyme phosphorylation; histopathology; immunohistochemistry; inflammation; male; nonhuman; polarization; protein expression; rat; real time polymerase chain reaction; T lymphocyte; Th17 cell
Citation Information
Scopus Citations: 53
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
